Harrow Completes Acquisition of TYRVAYA® Dry Eye Nasal Spray for $30M Upfront

Harrow, Inc. announced it has completed the acquisition of the worldwide rights (excluding Japan) to TYRVAYA®, a nasal spray for dry eye disease, from Viatris Inc. The acquisition agreement was amended on the closing date to exclude Japanese rights, which Viatris will retain, and fix the closing cash consideration.

Key Details

• Financial Terms: Harrow paid $30.0 million in cash at closing, funded with cash on hand. The agreement includes up to $70.0 million in additional contingent milestone payments based on sales thresholds through December 31, 2029.
• Agreement Structure: Harrow acquired all assets related to TYRVAYA® except for the rights in Japan. Viatris will pay Harrow tiered royalties on future net sales of the product in Japan.
• Closing Date: The acquisition was officially completed on October 1, 2026.